Results 1 - 10 of 28 : 1 2 3 Next
The drugmaker gets its licenses to distribute controlled substances reinstated.
King's Unstoppable Urge to Merge
Your potential acquisition isn't interested? Go for the hostile takeover!
The pharmaceutical makes an all-in bet on an unproven market.
A Potentially Painless PDUFA Date
King Pharmaceuticals and Pain Therapeutics get an appointment with the FDA.
Pain and King Start the Countdown
Who will win the race to get approval of an abuse-deterrent drug?
Another abuse-deterrent drug, cheaply purchased? Score!
Good News for Abuse-Resistant Drugs
The FDA has few objections to a potential new class of pain drugs.
With small caps, one indicator above all others bodes well for future performance.
These companies are buying back their shares. Should you join them?
A Competitive Stab at King and Pain
A new, dark-horse competitor arrives to fight King Pharma and Pain Therapeutics.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK